Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Continuity Biosciences, LLC
National Cancer Institute (NCI)
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Eli Lilly and Company
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
Boehringer Ingelheim
ViroMissile, Inc.
Arcus Biosciences, Inc.
Erasca, Inc.
PanTher Therapeutics
Washington University School of Medicine
Case Comprehensive Cancer Center
Baylor Research Institute
National Institutes of Health Clinical Center (CC)
ArriVent BioPharma, Inc.
Dana-Farber Cancer Institute
Amgen
Eli Lilly and Company
Angiex, Inc.
Poseida Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Rochester
University of Rochester
MacroGenics
Revolution Medicines, Inc.
Pheon Therapeutics
Abramson Cancer Center at Penn Medicine
University of Pennsylvania
General Oncology, Inc.
City of Hope Medical Center
SN BioScience
Zhejiang University
Cue Biopharma
Eli Lilly and Company
Eli Lilly and Company
TORL Biotherapeutics, LLC
Sun Yat-sen University
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center